iBio (IBIO) FCF Margin (2011 - 2025)

iBio (IBIO) posted quarterly FCF Margin of 5697.0% for Q3 2025, down 147.64% quarter-over-quarter from 2300.5% in Q2 2025.

iBio (IBIO) FCF Margin (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported FCF Margin for 15 consecutive years, with 5697.0% the latest figure, recorded in Q3 2025.

In Q3 2025, FCF Margin changed N/A year-over-year to 5697.0%; the TTM figure through Mar 2026 stood at 7386.67% (down 317893.0% YoY), while the FY2025 annual figure was 3829.0%, up 451056.0% from the prior year.
FCF Margin fell to 5697.0% in Q3 2025 per IBIO's latest filing, from 2300.5% in the prior quarter.
Across five years, FCF Margin topped out at 366.0% in Q1 2022 and bottomed at 12464.29% in Q3 2021.
Historically, FCF Margin has averaged 4379.85% across 5 years, with a median of 2300.5% in 2025.
On a YoY basis, FCF Margin climbed as much as 292517 bps in 2021 and fell as far as 1063770 bps in 2021.
iBio's FCF Margin stood at 12464.29% in 2021, then jumped by 97 bps to 366.0% in 2022, then slumped by 2818 bps to 10680.0% in 2023, then jumped by 82 bps to 1943.0% in 2024, then tumbled by 193 bps to 5697.0% in 2025.
Business Quant data shows IBIO's FCF Margin at 5697.0% in Q3 2025, 2300.5% in Q2 2025, and 1943.0% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	iBio	175.21 Mn	175.21 Mn	-	-

Download Data